Use of low-dose oral contraceptives and stroke in young women.

BACKGROUND Low-dose oral contraceptives are widely used, but there are limited data on the cerebrovascular risks associated with these medications. OBJECTIVE To determine whether use of low-dose oral contraceptives influences the risk for stroke. DESIGN Population-based case-control study. SETTING Women 18-44 years of age who resided in western Washington State between 1991 and 1995. PARTICIPANTS Patients with ischemic stroke (n = 60), hemorrhagic stroke (n = 102), and other types of stroke (n = 11) and controls identified through random-digit dialing (n = 485). MEASUREMENTS Details about oral contraceptive use and other risk factors for stroke were obtained through in-person interviews. RESULTS The estimated incidences of hemorrhagic stroke and ischemic stroke were 6.4 and 4.3 per 100,000 women-years, respectively. Compared with women who had never used oral contraceptives (after adjustment for risk factors for stroke), current users of low-dose oral contraceptives had estimated odds ratios of 0.93 (95% CI, 0.37 to 2.31) for hemorrhagic stroke and 0.89 (CI, 0.27 to 2.94) for ischemic stroke. Compared with past users of oral contraceptives, current users had odds ratios of 1.41 (CI, 0.67 to 2.96) for hemorrhagic stroke and 1.37 (CI, 0.49 to 3.81) for ischemic stroke. For past users compared with never users, the odds ratios were 0.59 (CI, 0.30 to 1.18) for hemorrhagic stroke and 0.57 (CI, 0.25 to 1.32) for ischemic stroke. The odds ratio for hemorrhagic stroke in current users of low-dose oral contraceptives containing norgestrel or levonorgestrel was elevated (3.23 [CI, 1.24 to 8.41]). Among patients with hemorrhagic stroke, the odds ratio for aneurysmal bleeding associated with current use of low-dose oral contraceptives containing norgestrel or levonorgestrel was 4.46 (CI, 1.58 to 12.53). CONCLUSION The overall risk for stroke and type of stroke was not increased among current users of low-dose oral contraceptives in the study population. Larger studies are needed to clarify both the relation of risk for stroke to past use of oral contraceptives and the possible association between current use of norgestrel-containing oral contraceptives and hemorrhagic stroke.